Biogen Inc. (Biogen) is a biopharmaceutical company discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The company markets products for multiple sclerosis, hemophilia A and B, and severe plaque psoriasis.
Biogen maintains an ethical approach to product quality and safety and supply chain management, including training employees on product safety best practices, articulation of an ethical marketing policy, and the implementation of supply chain initiatives to minimize counterfeit drug sales and human rights violations. Furthermore, the company is a member of Rx360, an industry-wide supply chain risk mitigation partnership, and audits its top suppliers to ensure compliance with its internal policies. Biogen also collaborates via partnerships in support of environmental advocacy for progressive climate policies and renewable energy mandates. However, the company does not solely address climate change through advocacy ; it also has a number of initiatives to minimize its operational impacts on energy, water and waste. For example, the company is both carbon neutral and produces zero waste-to-landfill, and has a goal of significantly reducing its normalized water use as well. Lastly, Biogen’s labor management strategy is robust, developing new talent through internships and fellowships, conducting regular employee surveys, and offering industry leading pay and non-pay benefits to its employees (e.g. stock benefits, life-insurance, 4-week paid sabbatical for long-term employees).
Despite a few initiatives to address issues of equitable health care within the United States, Biogen has not positioned itself well to capitalize off of selling more affordable products in developing markets, limiting the company’s ability to provide vulnerable communities with access to health care.
Industry: Health Care
Country: United States
To the best of our knowledge the above information is accurate and was obtained from sources we believe to be reliable. Neither the information presented above nor any opinion expressed shall be construed as an offer to sell or a solicitation to buy the security. The views expressed are those of portfolio management as of 12/31/16 and may not reflect current opinions or subsequent events.